KRAS vaccine significantly decreased surface tumors from ∼150 tumors per mouse lung in non-vaccinated mice to ∼21 tumors in vaccinated mice (Figure 2D), and decreased tumor volume nearly 90% (Figure 2E, 19.1mm3 to 2.4mm3). Here, KRAS is linked to neoplasm.